Trial · NCT05827016
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Up to 6 years | |
| Secondary | Achieving minimal residual disease (MRD) negativity in participants with complete response (CR) or better at 12 (± 3) months of maintenance treatment | Up to 6 years | |
| Secondary | Overall Survival | Up to 12 years | |
| Secondary | Recommended iberdomide dose for Stage 2 | Up to 1 year | |
| Secondary | Area under the iberdomide plasma concentration-time curve from time zero to tau | Up to 1 year | |
| Secondary | Area under the iberdomide plasma concentration-time curve within a dosing interval AUC (TAU) | Up to 1 year | |
| Secondary | Maximum iberdomide concentration (Cmax) | Up to 1 year | |
| Secondary | Time to maximum iberdomide plasma concentration (Tmax) | Up to 1 year | |
| Secondary | Number of participants with adverse events (AEs) | Up to 6 years | |
| Secondary | Progression-free survival on next line of treatment (PFS2) | Up to 6 years | |
| Secondary | Achieving MRD negativity in participants with CR or better at any time after the date of randomization | Up to 6 years | |
| Secondary | Conversion from MRD positive to MRD negative in participants with CR or better | Up to 6 years | |
| Secondary | Achievement of CR or better and maintaining MRD-negative status in 2 bone marrow aspirate assessments that are a minimum of 1 year apart, without any examination showing MRD positive status in between assessments | Up to 6 years | |
| Secondary | Time to progression (TTP) | Up to 6 years | |
| Secondary | Time to next treatment (TTNT) | Up to 6 years | |
| Secondary | Best response achieved prior to progressive disease (PD) | Up to 6 years | |
| Secondary | Patient-reported health-related quality of life (HRQoL) outcomes and multiple myeloma-related symptoms as measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life C30 questionnaire (QLQ-C30) | Up to 6 years | |
| Secondary | Patient-reported HRQoL outcomes and multiple myeloma-related symptoms as measured by the EORTC Quality of Life Multiple Myeloma Module (QLQ-MY20) | Up to 6 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05827016/registered